Tenaya Therapeutics, Inc.
TNYA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001858848
In the last 90 days, Tenaya Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 101 institutions reported holding it in 13F filings for Q2 2026, worth $39.7M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Tenaya Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 2 filings
- 2 insiders, $21.0K in total
- Insiders trading
- 2
- Net value
- −$21.0K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Tenaya Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Ali Faraz | Chief Executive Officer | 539,782 | Sep 11, 2026 | 6 |
| Tingley Whittemore | Chief Medical Officer | 263,073 | Sep 11, 2026 | 6 |
| Hyllengren Eric J | Chief Financial Officer | – | Jul 14, 2026 | 1 |
| Williams R Sanders | Director | – | May 29, 2026 | 1 |
| Walsh Jeffrey T. | Director | – | May 29, 2026 | 1 |
| Parschauer Karah Herdman | Director | – | May 29, 2026 | 1 |
| Lee June | Director | – | May 29, 2026 | 1 |
| Stehman-Breen Catherine | Director | – | May 29, 2026 | 1 |
| Srivastava Deepak | Director | 372,435Indirect | May 29, 2026 | 1 |
| Burroughs Amy L. | Director | – | May 29, 2026 | 1 |
| Higa Tomohiro | SVP, Finance | 118,267 | May 19, 2026 | 4 |
| Svennilson Peter | 10% Owner | 0Indirect | Feb 26, 2026 | 3 |
| Kutzkey Tim | 10% Owner | 0Indirect | Feb 26, 2026 | 3 |
| Column Group III-A, LP | 10% Owner | 0Indirect | Feb 26, 2026 | 3 |
| Column Group III, LP | 10% Owner | 0Indirect | Feb 26, 2026 | 3 |
| Column Group III GP, LP | 10% Owner | 0Indirect | Feb 26, 2026 | 3 |
| Column Group Opportunity III, LP | 10% Owner | 0Indirect | Feb 26, 2026 | 3 |
| TCG Opportunity III GP, LLC | 10% Owner | 0Indirect | Feb 26, 2026 | 3 |
| Column Group Opportunity III GP, LP | 10% Owner | 0Indirect | Feb 26, 2026 | 3 |
| Goeddel David V | Director, 10% Owner | 49,313,559Indirect | May 30, 2025 | 0 |
| Saito Chihiro | SVP, Accounting and Fin. Ops. | 60,983 | Nov 18, 2024 | 0 |
| Hoey Timothy | Chief Scientific Officer | 245,346 | Mar 6, 2024 | 0 |
| Patterson Leone D | Chief Fin. and Bus. Officer | 95,755 | Feb 27, 2024 | 0 |
| Chen Jin-Long | Director | – | Jun 12, 2023 | 0 |
| Casdin Capital, LLC | Director | 6,078,860Indirect | Nov 25, 2022 | 0 |
| Casdin Eli | Director | 6,078,860Indirect | Nov 25, 2022 | 0 |
| Casdin Partners Master Fund, L.P. | 10% Owner | 361,969Indirect | Aug 4, 2021 | 0 |
| Casdin Private Growth Equity Fund, L.P. | 10% Owner | 361,969Indirect | Aug 4, 2021 | 0 |
| Casdin Private Growth Equity Fund GP, LLC | 10% Owner | 361,969Indirect | Aug 4, 2021 | 0 |
| Kang JeenJoo | Director | 25,000 | Aug 4, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 19, 2023 (view filing)4:18 PM ET | Jan 17-18 | 2 days | Column Group III-A, LP and 5 others10% Owner | PPurchase | +185.2K | $2.51 | +$464.8K | +1.9%9.80M after | 2 lots |
| Jan 19, 2023 (view filing) | Jan 17-18 | 2 days | Goeddel David VDirector, 10% Owner | PPurchase | +185.2K | $2.51 | +$465.1K | +1.9%9.80M after | 2 lots |
| Dec 9, 2022 (view filing) | Nov 21 | 18 daysLate | Srivastava DeepakDirector | PPurchase | +230.8K | $2.60 | +$600.0K | +162.9%372.4K after | |
| Nov 25, 2022 (view filing)7:05 PM ET | Nov 17 | 8 daysLate | Casdin Capital, LLC and 1 otherDirector | PPurchase | +2.49M | $2.60 | +$6.48M | +69.5%6.08M after | |
| Nov 25, 2022 (view filing)7:05 PM ET | Nov 17 | 8 daysLate | Casdin Capital, LLC and 1 otherDirector | PPurchase | +1.35M | $2.60 | +$3.52M | –1.35M after | Derivative |
| Nov 23, 2022 (view filing)4:12 PM ET | Nov 21 | 2 days | Column Group III-A, LP and 5 others10% Owner | PPurchase | +9.62M | $2.60 | +$25.0M | New position9.62M after | Duplicate filing |
| Nov 23, 2022 (view filing) | Nov 21 | 2 days | Goeddel David VDirector, 10% Owner | PPurchase | +9.62M | $2.60 | +$25.0M | New position9.62M after | |
| Apr 28, 2022 (view filing) | Apr 26 | 2 days | Hoey TimothyChief Scientific Officer | SSale | −1.35K | $10.13 | −$13.7K | −0.7%198.6K after | |
| Aug 4, 2021 (view filing)6:33 PM ET | Aug 3 | 1 day | Casdin Capital, LLC and 3 others10% Owner | PPurchase | +850.0K | $15.00 | +$12.8M | +35.8%3.22M after | Duplicate filing |
| Aug 4, 2021 (view filing) | Aug 3 | 1 day | Casdin EliDirector, 10% Owner | PPurchase | +850.0K | $15.00 | +$12.8M | +35.8%3.22M after |